Skip to main content
Top
Published in: Diabetes Therapy 9/2020

Open Access 01-09-2020 | Insulins | Practical Approach

Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach

Authors: Bhawna Attri, Alpesh Goyal, Yashdeep Gupta, Nikhil Tandon

Published in: Diabetes Therapy | Issue 9/2020

Login to get access

Abstract

Background and Aim

The coronavirus disease 2019 (COVID-19) outbreak has rapidly crossed international boundaries and placed increasing demands on healthcare facilities worldwide. Patients with diabetes and uncontrolled blood glucose levels are at increased risk for poor clinical outcomes and in-hospital mortality related to COVID-19. Therefore, achieving good glycaemic control is of paramount importance among hospitalised patients with COVID-19. Basal-bolus insulin therapy is a safe and effective intervention for the management of hyperglycaemia in hospitalised patients. The aim of this article is to provide a practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus.

Methods

This guidance document was formulated based on the review of available literature and the combined personal experiences of the authors. We provide a comprehensive review on the use of the basal-bolus insulin regimen, including its principles, rationale, indications, prerequisites, initiation, and dose titration, and also suggest targets for blood glucose control and different levels of capillary blood glucose monitoring. Various case scenarios are used to illustrate how optimal glucose control can be achieved, such as through adjustments in doses of prandial and basal insulin, the use of correctional insulin dosing and changes in the timing and content of major and minor meals.

Conclusion

The practical guidance for the use of the basal-bolus insulin regimen in hospitalised patients with COVID-19 and diabetes mellitus presented here can be used for patients admitted to hospital for indications other than COVID-19 and for those in ambulatory care.
Appendix
Available only for authorised users
Literature
2.
go back to reference Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–10. Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: Prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr. 2020;14(4):303–10.
5.
go back to reference Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395‐403. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia—a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395‐403.
6.
go back to reference Zhu L, She Z, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1–10.CrossRef Zhu L, She Z, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020;31:1–10.CrossRef
7.
go back to reference McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am. 2012;41(1):175–201.PubMedPubMedCentralCrossRef McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. Endocrinol Metab Clin North Am. 2012;41(1):175–201.PubMedPubMedCentralCrossRef
8.
go back to reference Umpierrez G, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.PubMedCrossRef Umpierrez G, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(1):16–38.PubMedCrossRef
9.
go back to reference Moghissi ES, Korytkowski MT, Dinardo MM, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.PubMedPubMedCentralCrossRef Moghissi ES, Korytkowski MT, Dinardo MM, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009;32(6):1119–31.PubMedPubMedCentralCrossRef
12.
go back to reference Borcellati F, Rossetti P, Busciantella Ricci N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447–522.CrossRef Borcellati F, Rossetti P, Busciantella Ricci N, et al. Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. Diabetes Care. 2007;30:2447–522.CrossRef
13.
go back to reference Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017;34(1):29–38.PubMedCrossRef Heise T, Hövelmann U, Zijlstra E, Stender-Petersen K, Jacobsen JB, Haahr H. A comparison of pharmacokinetic and pharmacodynamic properties between faster-acting insulin aspart and insulin aspart in elderly subjects with type 1 diabetes mellitus. Drugs Aging. 2017;34(1):29–38.PubMedCrossRef
14.
go back to reference Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to obtaining accurate results. J Diabetes Sci Technol. 2009;3(4):971–80. Tonyushkina K, Nichols JH. Glucose meters: a review of technical challenges to obtaining accurate results. J Diabetes Sci Technol. 2009;3(4):971–80.
15.
go back to reference Kotwal N, Pandit A. Variability of capillary blood glucose monitoring measured on home glucose monitoring devices. Indian J Endocrinol Metab. 2012;16:S248–S251251.PubMedPubMedCentral Kotwal N, Pandit A. Variability of capillary blood glucose monitoring measured on home glucose monitoring devices. Indian J Endocrinol Metab. 2012;16:S248–S251251.PubMedPubMedCentral
19.
go back to reference Tsai CY, Lee SC, Hung CC, et al. False elevation of blood glucose levels measured by GDH-PQQ-based glucometers occurs during all daily dwells in peritoneal dialysis patients using icodextrin. Perit Dial Int. 2010;30:329–35.PubMedCrossRef Tsai CY, Lee SC, Hung CC, et al. False elevation of blood glucose levels measured by GDH-PQQ-based glucometers occurs during all daily dwells in peritoneal dialysis patients using icodextrin. Perit Dial Int. 2010;30:329–35.PubMedCrossRef
21.
go back to reference Chakraborty PP, Patra S, Bhattacharjee R, Chowdhury S. Erroneously elevated glucose values due to maltose interference in mutant glucose dehydrogenase pyrroloquinolinequinone (mutant GDH-PQQ) based glucometer. BMJ Case Rep. 2017;2017:bcr2017219928. https://doi.org/10.1136/bcr-2017-219928. Chakraborty PP, Patra S, Bhattacharjee R, Chowdhury S. Erroneously elevated glucose values due to maltose interference in mutant glucose dehydrogenase pyrroloquinolinequinone (mutant GDH-PQQ) based glucometer. BMJ Case Rep. 2017;2017:bcr2017219928. https://​doi.​org/​10.​1136/​bcr-2017-219928.
23.
go back to reference Ajjan R, Slattery D, Wright E. Continuous glucose monitoring: a brief review for primary care practitioners. Adv Ther 2019;36(3):579–96. Ajjan R, Slattery D, Wright E. Continuous glucose monitoring: a brief review for primary care practitioners. Adv Ther 2019;36(3):579–96.
24.
go back to reference Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41:2265–74.PubMedCrossRef Edelman SV, Argento NB, Pettus J, Hirsch IB. Clinical implications of real-time and intermittently scanned continuous glucose monitoring. Diabetes Care. 2018;41:2265–74.PubMedCrossRef
25.
go back to reference Funtanilla VD, Candidate P, Caliendo T, Hilas O. Continuous glucose monitoring: a review of available systems. P T. 2019;44(9):550–3.PubMedPubMedCentral Funtanilla VD, Candidate P, Caliendo T, Hilas O. Continuous glucose monitoring: a review of available systems. P T. 2019;44(9):550–3.PubMedPubMedCentral
26.
go back to reference Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am Fam Physician. 2010;81:1130–5.PubMed Nau KC, Lorenzetti RC, Cucuzzella M, Devine T, Kline J. Glycemic control in hospitalized patients not in intensive care: beyond sliding-scale insulin. Am Fam Physician. 2010;81:1130–5.PubMed
27.
go back to reference American Diabetes Association. Lifestyle management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S46–S60.CrossRef American Diabetes Association. Lifestyle management: standards of medical care in diabetes—2019. Diabetes Care. 2019;42(Suppl 1):S46–S60.CrossRef
28.
go back to reference Viswanathan V, Krishnan D, Kalra S, et al. Insights on medical nutrition therapy for type 2 diabetes mellitus: an Indian perspective. Adv Ther. 2019;36:520–47.PubMedPubMedCentralCrossRef Viswanathan V, Krishnan D, Kalra S, et al. Insights on medical nutrition therapy for type 2 diabetes mellitus: an Indian perspective. Adv Ther. 2019;36:520–47.PubMedPubMedCentralCrossRef
33.
go back to reference Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13:217–25.PubMedCrossRef Dhatariya K. Blood ketones: measurement, interpretation, limitations, and utility in the management of diabetic ketoacidosis. Rev Diabet Stud. 2016;13:217–25.PubMedCrossRef
36.
go back to reference Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother. 2018;52(1):86–90.PubMedCrossRef Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother. 2018;52(1):86–90.PubMedCrossRef
37.
go back to reference Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073–81.PubMedPubMedCentralCrossRef Tamez-Pérez HE, Quintanilla-Flores DL, Rodríguez-Gutiérrez R, González-González JG, Tamez-Peña AL. Steroid hyperglycemia: prevalence, early detection and therapeutic recommendations: a narrative review. World J Diabetes. 2015;6:1073–81.PubMedPubMedCentralCrossRef
39.
go back to reference Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis. Curr Diabetes Rep. 2018;18:75.CrossRef Iyengar R, Franzese J, Gianchandani R. Inpatient glycemic management in the setting of renal insufficiency/failure/dialysis. Curr Diabetes Rep. 2018;18:75.CrossRef
40.
go back to reference Sudha MJ, Salam HS, Viveka S, Udupa AL. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8:64–8.PubMedPubMedCentralCrossRef Sudha MJ, Salam HS, Viveka S, Udupa AL. Assessment of changes in insulin requirement in patients of type 2 diabetes mellitus on maintenance hemodialysis. J Nat Sci Biol Med. 2017;8:64–8.PubMedPubMedCentralCrossRef
41.
go back to reference Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27:135–45.PubMedPubMedCentralCrossRef Rhee CM, Leung AM, Kovesdy CP, Lynch KE, Brent GA, Kalantar-Zadeh K. Updates on the management of diabetes in dialysis patients. Semin Dial. 2014;27:135–45.PubMedPubMedCentralCrossRef
42.
go back to reference Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14:241–6.PubMedPubMedCentralCrossRef Singh AK, Singh A, Shaikh A, Singh R, Misra A. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: a systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020;14:241–6.PubMedPubMedCentralCrossRef
45.
go back to reference Tandon N, Kalra S, Balhara YP, et al. Forum for injection technique and therapy expert recommendations, India: the Indian recommendations for best practice in insulin injection technique, 2017. Indian J Endocrinol Metab. 2017;21:600.PubMedPubMedCentralCrossRef Tandon N, Kalra S, Balhara YP, et al. Forum for injection technique and therapy expert recommendations, India: the Indian recommendations for best practice in insulin injection technique, 2017. Indian J Endocrinol Metab. 2017;21:600.PubMedPubMedCentralCrossRef
Metadata
Title
Basal-Bolus Insulin Regimen for Hospitalised Patients with COVID-19 and Diabetes Mellitus: A Practical Approach
Authors
Bhawna Attri
Alpesh Goyal
Yashdeep Gupta
Nikhil Tandon
Publication date
01-09-2020
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 9/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-020-00873-3

Other articles of this Issue 9/2020

Diabetes Therapy 9/2020 Go to the issue